Treatment of haematological malignancies has improved substantially over the past two decades; survival times have doubled and the prospect of cure of several diseases is based on the introduction of novel drugs. However, acute myeloid leukaemia was a notable exception with few new treatments available.¹ Survival in this disease has remained dismal, especially in elderly patients with acute myeloid leukaemia not eligible for intensive induction chemotherapy. This situation was mainly due to the fact that the survival benefit from treatment of acute myeloid leukaemia was limited to patients who achieved complete remission or, at least, blast clearance.

中文翻译：

---

急性髓细胞白血病诱导缓解的新选择

在过去的二十年中，血液系统恶性肿瘤的治疗已有很大改善。生存时间增加了一倍，几种疾病的治愈前景基于新药的引入。但是，急性髓细胞性白血病是一个明显的例外，几乎没有可用的新疗法。¹该病的存活率仍然令人沮丧，尤其是在不适合进行密集诱导化疗的急性髓性白血病的老年患者中。这种情况主要是由于以下事实：治疗急性髓细胞性白血病的生存获益仅限于完全缓解或至少清除了胚层清除的患者。